Humana’s latest exec hired from CMS

Health insurer Humana has snagged the top doctor at CMS, Kate Goodrich, MD, who served as chief medical officer of CMS and director of the Center for Clinical Standards and Quality. She will take her new role as senior vice president with Humana in February.

The news was first reported by Politico.

Goodrich has served as the director of Quality Measurement & Value-Base Incentives Group since 2012. She previously served as senior advisor to the director of CCSQ and as senior medical officer in the Office of the Assistant Secretary for Planning and Evaluation.

The hire is a big nab for Humana, which has increasingly focused on strategically aligning for value-based and integrated care. She was recently ranked as the 13th most influential person in healthcare by Modern Healthcare­–ahead of both HHS Secretary Alex Azar and Nancy Pelosi.

At the same time, CMS is losing another executive––Mona Siddiqui, MD, MPH, who wrote in a blog post that she will be leaving her role as chief data officer at the HHS Office of the CTO. She served in the office for three years.

Humana did not immediately respond to a media inquiry from Health Exec.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.